Chromaffin cell transplants for alleviation of chronic pain

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Treatment of intractable pain with parenteral, subarachnoid, or epidural narcotics is often unsatisfactory due to tolerance and other systemic complications that accompany increasing dosages of these drugs. Other disadvantages include the potential infections with implantable pumps and the inconvenience of repeated narcotic administration. During the past several years, studies at the author's laboratory indicated that transplantation of adrenal medullary tissue or isolated chromaffin cells into the spinal subarachnoid space can significantly reduce pain in several rodent models without resulting in development of tolerance. Adrenal medullary chromaffin cells were selected because they produce high levels of both opioid peptides and catecholamines, agents that independently, and possibly synergistically, reduce pain when injected locally into the spinal subarachnoid space. The adrenal medullary transplants survive for prolonged periods, and continue to produce high levels of both catecholamines and met-enkephalin. These transplants reduce pain in two rodent chronic pain models, an arthritis model and a peripheral neuropathy model, both of which closely resemble human chronic pain syndromes. The success of the animal studies has led to initiation of human clinical trials in patients with chronic cancer pain; results are promising.

Original languageEnglish
Pages (from-to)24-28
Number of pages5
JournalASAIO Journal
Volume38
Issue number1
StatePublished - Jan 1 1992
Externally publishedYes

Fingerprint

Chromaffin Cells
Transplants
Chronic Pain
Subarachnoid Space
Narcotics
Pain
Catecholamines
Rodentia
Intractable Pain
Methionine Enkephalin
Opioid Peptides
Peripheral Nervous System Diseases
Arthritis
Transplantation
Clinical Trials
Animals
Pumps
Tissue
Infection
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Biophysics
  • Bioengineering

Cite this

Chromaffin cell transplants for alleviation of chronic pain. / Sagen, Jacqueline.

In: ASAIO Journal, Vol. 38, No. 1, 01.01.1992, p. 24-28.

Research output: Contribution to journalArticle

@article{8a8a7a166f0945aa982a2d0a9c2141d6,
title = "Chromaffin cell transplants for alleviation of chronic pain",
abstract = "Treatment of intractable pain with parenteral, subarachnoid, or epidural narcotics is often unsatisfactory due to tolerance and other systemic complications that accompany increasing dosages of these drugs. Other disadvantages include the potential infections with implantable pumps and the inconvenience of repeated narcotic administration. During the past several years, studies at the author's laboratory indicated that transplantation of adrenal medullary tissue or isolated chromaffin cells into the spinal subarachnoid space can significantly reduce pain in several rodent models without resulting in development of tolerance. Adrenal medullary chromaffin cells were selected because they produce high levels of both opioid peptides and catecholamines, agents that independently, and possibly synergistically, reduce pain when injected locally into the spinal subarachnoid space. The adrenal medullary transplants survive for prolonged periods, and continue to produce high levels of both catecholamines and met-enkephalin. These transplants reduce pain in two rodent chronic pain models, an arthritis model and a peripheral neuropathy model, both of which closely resemble human chronic pain syndromes. The success of the animal studies has led to initiation of human clinical trials in patients with chronic cancer pain; results are promising.",
author = "Jacqueline Sagen",
year = "1992",
month = "1",
day = "1",
language = "English",
volume = "38",
pages = "24--28",
journal = "ASAIO Journal",
issn = "1058-2916",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Chromaffin cell transplants for alleviation of chronic pain

AU - Sagen, Jacqueline

PY - 1992/1/1

Y1 - 1992/1/1

N2 - Treatment of intractable pain with parenteral, subarachnoid, or epidural narcotics is often unsatisfactory due to tolerance and other systemic complications that accompany increasing dosages of these drugs. Other disadvantages include the potential infections with implantable pumps and the inconvenience of repeated narcotic administration. During the past several years, studies at the author's laboratory indicated that transplantation of adrenal medullary tissue or isolated chromaffin cells into the spinal subarachnoid space can significantly reduce pain in several rodent models without resulting in development of tolerance. Adrenal medullary chromaffin cells were selected because they produce high levels of both opioid peptides and catecholamines, agents that independently, and possibly synergistically, reduce pain when injected locally into the spinal subarachnoid space. The adrenal medullary transplants survive for prolonged periods, and continue to produce high levels of both catecholamines and met-enkephalin. These transplants reduce pain in two rodent chronic pain models, an arthritis model and a peripheral neuropathy model, both of which closely resemble human chronic pain syndromes. The success of the animal studies has led to initiation of human clinical trials in patients with chronic cancer pain; results are promising.

AB - Treatment of intractable pain with parenteral, subarachnoid, or epidural narcotics is often unsatisfactory due to tolerance and other systemic complications that accompany increasing dosages of these drugs. Other disadvantages include the potential infections with implantable pumps and the inconvenience of repeated narcotic administration. During the past several years, studies at the author's laboratory indicated that transplantation of adrenal medullary tissue or isolated chromaffin cells into the spinal subarachnoid space can significantly reduce pain in several rodent models without resulting in development of tolerance. Adrenal medullary chromaffin cells were selected because they produce high levels of both opioid peptides and catecholamines, agents that independently, and possibly synergistically, reduce pain when injected locally into the spinal subarachnoid space. The adrenal medullary transplants survive for prolonged periods, and continue to produce high levels of both catecholamines and met-enkephalin. These transplants reduce pain in two rodent chronic pain models, an arthritis model and a peripheral neuropathy model, both of which closely resemble human chronic pain syndromes. The success of the animal studies has led to initiation of human clinical trials in patients with chronic cancer pain; results are promising.

UR - http://www.scopus.com/inward/record.url?scp=0026608012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026608012&partnerID=8YFLogxK

M3 - Article

C2 - 1372836

AN - SCOPUS:0026608012

VL - 38

SP - 24

EP - 28

JO - ASAIO Journal

JF - ASAIO Journal

SN - 1058-2916

IS - 1

ER -